Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification).~* Age from18 to 59 years, eligible for transplant.~* Patient not previously treated.~* Baseline FDG-PET Scan (PET0) performed before any treatment with at least one hypermetabolic lesion.~* Index prognostic factors (IPI) 2 or 3.~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies £ 4 weeks (except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* Any other histological type of lymphoma.~* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Poor renal function (creatinin level \>150 mmol/l), poor hepatic function (total bilirubin level \>30 mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ)cervical carcinoma.~* Any serious active disease (according to the investigator's decision).~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy.~* Pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception~* Adult patient under tutelage.~* Impossibility to performed a baseline PET scan (PET0) before randomization and treatment beginning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- R-CHOP-14 (Type: EXPERIMENTAL): R-CHOP14 induction regimen
- R-ACVBP14 (Type: EXPERIMENTAL): R-ACVBP14 induction regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).